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Purpose: Low-dose tamoxifen has comparable antiproliferative effect to the standard dose of 20 mg/day in biomarker trials, but its clinical efficacy is unclear. We assessed low-dose tamoxifen, 10 mg on alternate days on ipsilateral recurrence in ductal carcinoma in situ (DCIS) patients treated in a referral Institution between 1996 and 2008.
Methods: Following breast conserving surgery, women with DCIS received radiotherapy and/or low-dose tamoxifen upon clinical judgment and patient preferences. Multivariate Cox regression analyses were used with and without confounding factors.





Ductal carcinoma in situ (DCIS) represents a large spectrum of non-infiltrating breast lesions of the duct whose management may include surgery, radiotherapy and hormonal therapy1-3. However, a standard treatment after surgery does not exist and nearly all aspects of treatment are controversial, including the need for any treatment for some screen detected lesions4, the extent of surgery5, the use of radiotherapy6,7, and/or adjuvant endocrine treatment8. 
Radiotherapy has been shown to halve both in situ and invasive recurrences in four phase III trials8-10, two of which have also demonstrated that tamoxifen 20 mg/day reduces the risk of ipsilateral and contralateral events by approximately 30% both at 10 and 15 years8,9. Retrospective evaluation of estrogen receptor (ER) in a subgroup of 732 patients from the NSABP-P24 trial showed that tamoxifen reduced subsequent breast events by 51% in ER-positive DCIS11. 
However, neither tamoxifen nor radiotherapy have shown an improvement on survival and both treatments may induce rare but serious adverse events such as endometrial cancers and venous thromboembolism following tamoxifen12,13 or cardiac side effects 14 and second malignancies following radiotherapy15. These adverse events may limit the uptake and adherence to treatment for the prevention of recurrences in DCIS16.







The cohort includes all consecutive women diagnosed with a primary DCIS, between January 1996 and December 2008 who underwent breast surgery at the European Institute of Oncology (IEO), Milan, Italy, and were followed up for at least five years after surgery. Although this was not a randomized clinical trial, the IEO IRB approved inclusion of all women in an observational study with a dedicated database for research. All patients who underwent breast conserving surgery (BCS), with central pathology and 4-immunohistochemistry (IHC) parameters (ER, PgR, Ki67%, HER2-neu) were included. Patients undergoing total mastectomy, taking full dose tamoxifen (20 mg/day) or different antiestrogens or aromatase inhibitors were excluded from the present analysis. Relevant clinical data, including demographics, body mass index (BMI), personal medical history, concomitant medications, participation in a clinical trial and survival data were recorded. Follow up data included survival status, date of any new breast event, other cancer or death. 

Treatment assignment
Since 1996, all patients with DCIS received radiotherapy or tamoxifen based on clinical judgment and patient preferences in a dedicated clinical service. Starting from 2001, all cases were systematically recorded during a weekly multidisciplinary meeting to provide the most appropriate treatment or participation in clinical trials. Following institutional policy, indication for postoperative radiotherapy in this study population were very restrictive. Radiotherapy was generally not offered to low grade, while it was offered to moderately differentiated with tumor necrosis, to comedo carcinoma subtype and to all poorly differentiated DCIS. Histological size, age, width of negative margins and other risk factors had no implications on the indication to radiotherapy. However, given the increasing evidence for a benefit of radiotherapy over time22,23, physician’s attitude to prescribe radiotherapy increased with time. The most common radiation schedule was 50 Gy in 25 fractions given on 5 days weekly to the whole breast. The boost to the tumor (14-16 Gy) was applied only in case of positive margins not undergoing re-excision.

The indication to prescribe low-dose tamoxifen was less stringent. Whereas up to 2003 no hormonal treatment was routinely recommended outside a clinical trial, starting from January 2004, physicians started to offer low-dose tamoxifen, unless contraindicated, in women with ER-positive (≥1%) and high risk DCIS based on high grade, tumor necrosis and positive margins. Given the positive results of several phase II biomarker clinical trials run at IEO18,19,24,25, tamoxifen dose was either 10 mg every other day in approximately 75% of the cases (the 5 mg tablet is not marketed) or 20 mg once a week in 25% of the cases for five years. Patients were counseled by a dedicated team of physicians from a single Division about treatment benefits and risks, leaving the final decision to their preferences unless enrolled in a clinical trial. Women were followed up regularly in the clinic or at least yearly by the phone if unable to attend the Institute.

Statistical methods
The primary endpoint of this analysis was the effect of low dose tamoxifen on ipsilateral recurrence. Only women who underwent breast conserving surgery were included in this analysis (N=1091). To assess the effect of the low dose tamoxifen comparison, analysis was restricted to those women with ER-positive DCIS at baseline (N=883). For the radiotherapy comparison, all women, irrespective of ER-status were included (N=1091). Only the first new breast event was recorded, thus a distant new breast event that occurred after a local event was not available for analysis.






Between 1996 and 2008 a total of 1,091 consecutive women underwent BCS at IEO for DCIS. 80% of all DCIS were mammographically detected whereas 19% were detected due to palpable nodules. Radiotherapy was administered to 544 subjects. 883 women had an ER-positive DCIS, of whom 467 (52.9%) received low dose tamoxifen. The majority of women included in this analysis came from observational studies (N=993), 95 women were included in randomized controlled trials, and for three women the type of study was missing.
Table 1 shows patient and tumor characteristics according to radiotherapy or low dose tamoxifen treatment. Overall, the median age group was 53 years (IQR 46-62), with 99 women (9%) being aged 40 years or younger. Women who received low dose tamoxifen were significantly younger, had higher positive PgR levels, and had lower HER2 overexpression (all p<0.001) compared to women not receiving low dose tamoxifen,.Women who received radiotherapy had significantly higher grade, larger tumour size, presence of necrosis, higher percentage of margins involved, higher Ki67 level, ER absence and HER2 overexpression than those who did not receive radiotherapy (all p<0.01) (Table 1).
After a median follow-up of 7.73 years (IQR, 5.81-9.67) 8163 women-years of follow-up have been accrued. A total of 297 new breast events were observed, including 235 ipsilateral recurrences and 62 contralateral events. Median time on low dose tamoxifen was 4.95 years (IQR 2.58-5.00), with a total of 242 new breast events in this cohort.
Table 2a shows the number and type of breast events according to low dose tamoxifen use. After adjustment for radiotherapy use, age, BMI, margins and grade, there was a 30% significant reduction of any breast event with tamoxifen (adjusted HR=0.70, 95% confidence interval [CI], 0.54-0.91, p=0.007). The effect of low dose tamoxifen was significant for ipsilateral DCIS recurrence (adjusted HR= 0.66, 95% CI, 0.49-0.88, p=0.005), but not for ipsilateral invasive recurrence (adjusted HR= 0.78, 95% CI, 0.53-1.15, p=0.21) or contralateral breast cancer (adjusted HR= 0.89, 95% CI, 0.51-1.55, p=0.68).
Table 2b shows the number and type of breast events according to radiation therapy. After adjustment for tamoxifen use, age, BMI, margins and grade, there was a significant 45% reduction of any breast event (adjusted HR=0.55, 95% CI, 0.42-0.72, p<0.001). The effect of radiotherapy was significant both on ipsilateral DCIS recurrence (adjusted HR= 0.40, 95% CI, 0.25-0.63, p<0.001) and ipsilateral invasive recurrence (adjusted HR= 0.57, 95% CI 0.37-0.86, p=0.007), but not on contralateral breast cancers (adjusted HR= 0.93, 95% CI, 0.49-1.74, p=0.81).
Low-dose tamoxifen was significantly more effective in women older than 50 years of age for all recurrences (adjusted HR=0.51, 95% CI, 0.33-0.77, p=0.002) and ipsilateral recurrences (adjusted HR=0.43, 95% CI, 0.26-0.72) than in women aged 50 or younger p-interaction=0.03) (Figure 1). Similarly, radiotherapy was much more effective in women older than aged 50 years with a 43% percent reduction on all breast recurrences and a 44% reduction on ipsilateral recurrences than in women aged 50 or younger (p-interaction=0.2), respectively (Figure 1). Results were not different for radiotherapy when the analysis was restricted to the subgroup of 883 patients with ER-positive DCIS (data not shown). 





Our observational study shows a significant overall 30% reduction of any type of recurrence in women with high risk ER-positive DCIS with low dose tamoxifen, an effect which is comparable to those obtained with the standard dose in the two phase III trials conducted in women with a lower risk and unknown hormone receptor status DCIS8,9. This magnitude of effect was obtained after adjustment for confounding factors, which increased the estimate of tamoxifen benefit since younger women received the drug more frequently than older women. Low-dose tamoxifen also decreased DCIS all ipsilateral recurrence by 34%, but did not significantly reduce ipsilateral invasive or contralateral recurrence specifically. This observation is in line with the UK-ANZ trial8 which showed no evidence of a significant reduction of ipsilateral invasive recurrence with tamoxifen, whereas the NSABP-B24 trial showed a 32% reduction of invasive recurrence with tamoxifen9. Our findings also showed no significant effect of low-dose tamoxifen on contralateral breast cancer, a finding in contrast with both phase III trials8,9.
The notion that this was mostly a high risk population of DCIS typically seen in a national referral center is illustrated by the high rate of events in the untreated groups, approximately 4% per year, which is around 4-5 times greater than that seen in a low risk, older screening population of DCIS27 and more than twice higher than in the phase III trials of tamoxifen versus placebo8,9 or in the most recent tamoxifen versus anastrozole trials (IBIS2 and B35)28,29. In our population, radiotherapy induced a remarkable 45% reduction of any breast event, consistent with the results of phase III trials8,9, notwithstanding the fact that women who received radiotherapy had worse prognostic factors such as higher grade, larger size, margin involvement and high Ki67 compared with those who did not receive radiotherapy. After adjustment for tamoxifen use, there also was a significant 51% reduction of DCIS recurrence and 41% reduction of invasive recurrence under radiotherapy, but not of contralateral breast cancers, as in prior trials8,9.
Our results indicate that the effect of low dose tamoxifen was significantly modified by age, since older women aged exhibited a 50% reduction of any recurrence, whereas women aged 50 years or younger had an approximately 15% non-significant reduction of any event. A similar, albeit not significant, interaction with age was noted for radiotherapy, which showed very little effect in women aged 50 or younger. One possible explanation for the differential effect of low-dose tamoxifen according to age might be due to an inadequate control of the increased peripheral estrogens. We have previously shown that estrogen levels tend to increase in premenopausal women under low dose tamoxifen by a similar extent than the standard dose30. However, the lower efficacy observed for radiotherapy in women aged 50 or younger, in line with the overview of randomized trials of radiotherapy31 as well as in the 20 year follow-up of the SweDCIS trial10, seems to suggest that additional mechanisms are involved. Importantly, the effect of tamoxifen on DCIS recurrence showed an age related effect also in the updated analysis of the NSABP B-24 trial9, with a clear benefit for radiotherapy only in women aged 55-64 years, and no benefit of radiotherapy in all other age groups. The lower extent of risk reduction in younger women may suggest a possible benefit of boost irradiation, which is currently under investigation in several phase III studies (IBCSG trial 38-10/BIG 3-07/TROG 07.01, EORTC 22085-10083)32 and BONBIS33. Tamoxifen 20 mg/day is known to exert primary preventive efficacy also in women aged 50 or younger, although the magnitude of protection increases with age13. Also, in the worldwide overview of adjuvant studies of tamoxifen there is evidence of a greater effect on recurrence and mortality in older women34 with a ratio of annual event rate of 0.63 (SE 0.05), 0.72 (SE 0.05), 0.54 (SE 0.04) and 0.50 (SE 0.15) in women aged <45, 45–54, 55–69 and ≥70 years, respectively.
The effects of anastrozole in comparison with tamoxifen in postmenopausal women with ER positive DCIS have recently been reported in two large trials, NSABP B-3528 and IBIS-II29. Anastrozole significantly decreased all breast events compared with tamoxifen only in women younger than 60 years in the NSABP B-35 trial28, whereas no clear efficacy differences were seen in IBIS-II29. In line with recent SEER data,35, prognosis was excellent in both trials, with less than 0.5% total breast cancer mortality after at least 7 years median follow-up. Toxicity was different without a clear superiority of one agent over the other, providing an opportunity for a personalized treatment based on individual host characteristics. Young age or premenopausal status was the strongest prognostic factor for recurrence in DCIS, consistent with previous findings22,35-38. Positive margins, high Ki67, low BMI and, to a lower extent, high grade were independent risk factors for ipsilateral recurrence. While positive margins and high Ki67 have unequivocally been shown to be prognostic in several series7,39-41, the strong independent protective effect of higher BMI is remarkable. In the Wisconsin cohort study42, premenopausal women with high BMI had a lower risk of recurrence, in line with the protective effect of high BMI on first breast cancer and breast cancer prognosis seen in premenopausal women43. However, another study found an opposite effects of high BMI on ipsilateral recurrence44. While we did not find evidence for an interaction of BMI with menopausal status on recurrence, additional studies are necessary to shed light into this intriguing finding.
Our cohort exhibited a low rate of overall and breast cancer deaths compared with randomised clinical trials8,9. We also observed a trend to a reduction of breast cancer and overall mortality in the low dose tamoxifen group which is difficult to explain and may well be due to chance. Notably, however, we found no excess of endometrial cancer in the low dose tamoxifen group, suggesting that a dose reduction might be safer at this level, as predicted by previous biomarker trials18,19.





Cumulative incidence of ipsilateral recurrence by treatment (low dose tamoxifen, upper panels, radiotherapy, bottom panels) and age (≤50 years, left panels, >50 years, right panels). 


Table 1. Patient and tumor characteristics by treatment group
	No tamoxifen(n=416)	Low Tamoxifen(n=467)	No RT(n=547)	RT(n=544)
Age (years), median (IQR)	54 (46-64)	50 (45-58)*	52 (45-62)	54 (47-62)
BMI (kg/m2), median (IQR)	23.2 (21.1-26.2)	22.7 (20.8-25.4)	23.0 (20.9-26.1)	23.1 (21.0-25.7)
Grade				
Low	107 (25.7%)	106 (22.7%)	197 (36.0%)	22 (4.0%)
Intermediate	245 (58.9%)	282 (60.4%)	316 (57.8%)	281 (51.7%)
High	64 (15.4%)	79 (16.9.0%)	34 (6.2%)	241 (44.3%)*
Tumor size (287 missing for tam, 344 missing for RT comparison)				
< 1cm	94 (22.6%)	91 (19.5%)	125 (22.9%)	92 (16.9%)
1-2 cm	118 (28.4%)	115 (24.6%)	146 (26.7%)	148 (27.2%)
> 2 cm	80 (19.2%)	98 (21.0%)	102 (18.7%)	134 (24.6%)*
Palpable nodule				
No	310 (74.5%)	353 (75.6%)	411 (75.1%)	401 (73.7%)
Yes	79 (19%)	88 (18.8%)	106 (19.4%)	107 (19.7%)
Margins (3 missing)				
Involved	9 (2.2%)	14 (3.0%)	8 (1.5%)	18 (3.3%)
Not involved	406 (97.6%)	451 (96.6%)	537 (98.2%)	524 (96.3%)*
Necrosis				
Absent	220 (52.9%)	215 (46.0%)	367 (67.1%)	126 (23.2%)
Present	196 (47.1%)	252 (54.0%)*	180 (32.9%)	418 (76.8%)*
ER				
Negative (0%)	-	-	57 (10.4%)	151 (27.8%)
Positive	416 (100%)	467 (100%)	490 (89.6%)	393 (72.2%)*
PgR(1 missing)				
Negative (0%)	68 (16.4%)	53 (11.4%)	114 (20.8%)	214 (39.3%)
Positive	348 (83.6%)	413 (88.4%)*	432 (79.0%)	330 (87.6%)*
Ki67% (4 missing)				
<14%	226 (54.3%)	243 (52.0%)	356 (65.1%)	139 (25.6%)
>14%	187 (45.0%)	223 (47.8%)	190 (34.7%)	402 (73.9%)*
HER2 				
Negative/equivocal	335 (80.5%)	381 (81.6%)	445 (81.4%)	323 (59.4%)
Positive	81 (19.5%)	86 (18.4%)	102 (18.7%)	221 (40.6%)*


Table 2a. Number of new breast events according to low dose tamoxifen use
	No Tam(N=416)	Tam(N=467)	Adjusted HR (95% CI)*P-value
New breast event	130 (31.3%)	112 (24.0%)	0.70 (0.54-0.91)P=0.007
  All ipsilateral#	103 (24.8%)	86 (18.4%)	0.66 (0.49-0.88)P=0.005
  All contralateral#	26 (6.3%)	25 (5.4%)	0.89 (0.51-1.55)P=0.68
Invasive	76 (18.3%)	72 (15.4%)	0.78 (0.56-1.09)P=0.14
  Ipsilateral	55 (13.2%)	54 (11.6%)	0.78 (0.53-1.15)P=0.21
  Contralateral	21 (5.1%)	18 (3.9%)	0.79 (0.42-1.50)P=0.47
DCIS	54 (13.0%)	40 (8.6%)	0.60 (0.39-0.90)P=0.014
  Ipsilateral	48 (11.5%)	32 (6.9%)	0.53 (0.34-0.83)P=0.006
  Contralateral	5 (1.2%)	7 (1.5%)	1.33 (0.41-4.32)P=0.63
*Adjusted for radiotherapy, age, BMI, margins, DCIS grade; #2 laterality missing


Table 2b. Number of new breast events according to radiotherapy
	No RT(N=547)	RT(N=544)	Adjusted HR (95% CI)*P-value
New breast event	171 (31.3%)	126 (23.2%)	0.55 (0.42-0.72)P<0.001
  All ipsilateral#	138 (25.2%)	97 (17.8%)	0.48 (0.35-0.66)P<0.001
  All contralateral#	32 (5.9%)	27 (5.0%)	0.93 (0.49-1.74)P=0.81
Invasive	101 (18.5%)	73 (13.4%)	0.59 (0.41-0.86)P=0.005
  Ipsilateral	75 (13.7%)	56 (10.3%)	0.57 (0.37-0.86)P=0.007
  Contralateral	26 (4.8%)	17 (3.1%)	0.70 (0.33-1.50)P=0.36
DCIS	70 (12.8%)	53 (9.7%)	0.49 (0.32-0.75)P=0.001
  Ipsilateral	63 (11.5%)	41 (7.5%)	0.40 (0.25-0.63)P<0.001
  Contralateral	6 (1.1%)	10 (1.8%)	1.89 (0.56-6.39)P=0.3
*Adjusted for tamoxifen, BMI, margins, DCIS grade; # 3 laterality missing


Table 3: Mean annual rates (per 1000, 95%CI) for recurrences and deaths according to treatment
	No tamoxifen(N=416)	Low dose tamoxifen(N=467)	No radiotherapy(N=547)	Radiotherapy(N=544)
All recurrences	42.0 (35.4-49.9)	31.4 (26.1-37.8)	39.7 (33.8-46.6)	32.2 (26.3-39.3)
Ipsilateral recurrence	33.3 (27.4-40.4)	24.1 (19.5-29.8)	31.6 (26.3-37.8)	24.4 (19.4-30.7)
Breast cancer death	0.65 (0.16-2.58)	0.56 (0.14-2.24)	1.22 (0.51-2.94)	0.74 (0.24-2.28)
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